Health
Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommend Use of FES PET Imaging for Lobular Breast Cancer
ARLINGTON HEIGHTS, Ill., May 30, 2025--GE HealthCare announced that the NCCN Guidelines for Clinical Oncology now recommend FES PET for systemic staging in patients with metastatic ILC.
About this update from Ge Healthcare Technologies Inc.
[{"type":"image","alt":"PET/CT scan with Cerianna™ (fluoroestradiol F18) injection for patient with ILC reveals bone metastases","displaySize":"","headline":null,"caption":"PET/CT scan with Cerianna™ (fluoroestradiol F18) injection for patient with ILC reveals bone metastases","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":308,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/07128a15633bd61b91a33214ca38d7af"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n9Pexo32xk3klkUEEhg8BA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY1NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/07128a15633bd61b91a33214ca38d7af","width":308,"height":480}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":6570,"height":2242,"url":"https://media.zenfs.com/en/business-wire.com/e7f365e4e11d48f9dad0c8c44a87d681"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0PP1jylFCCINprTvpWPWHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e7f365e4e11d48f9dad0c8c44a87d681","width":960,"height":328},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/He00yA0VtMmPS37wybk6wg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e7f365e4e11d48f9dad0c8c44a87d681","width":1200,"height":409}}},{"type":"list","items":[{"val":[{"type":"text","content":"NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater diagnostic accuracy, earlier interventions, better clinical decision-making and broader insurance coverage for breast cancer patients.","length":277,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"GE HealthCare’s Cerianna (fluoroestradiol F18) injection is the first and only U.S. Food and Drug Administration (FDA) approved imaging agent to help clinicians assess estrogen receptor positive (ER+) lesion status in recurrent or metastatic breast cancer.","length":256,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":533,"olType":false},{"type":"text","content":"ARLINGTON HEIGHTS, Ill., May 30, 2025--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that the NCCN Clinical Practice Guid...